Skip to main content

Table 2 Predicted HLA II binding profile of conserved and experimentally verified HCMV-specific CD4 T cell epitopes

From: Computational assembly of a human Cytomegalovirus vaccine upon experimental epitope legacy

EpitopeAntigen geneAntigen accessiona HLA II restrictionb Extended HLA II restrictionc PPC (%)
SIYVYALPLKMLNIPUL83Q6SW59DRB1*07, DRB1*15:01DRB1*01:01, DRB1*03:01, DRB1*07:01, DRB1*11:01, DRB1*15:0163.95
KLFMHVTLGSDVEEDLTMTRUL83Q6SW59DRB1*03DRB1*03:01, DRB1*04:05, DQA1*05:01/ DQB1*02:01, DQA1*05:01/ DQB1*03:0148.03
LPVADAVIHASGKQMWQARLUL83Q6SW59DRB1*03DRB1*01:01, DQA1*05:01/ DQB1*02:01, DQA1*05:01/ DQB1*03:0142.11
GPISGHVLKAVFSRGUL83Q6SW59HLA class IIDRB1*01:01, DQA1*05:01/ DQB1*02:01, DQA1*05:01/ DQB1*03:0142.11
CSMENTRATKMQVIGUL83Q6SW59HLA class IIDRB1*07:01, DQA1*01:02/ DQB1*06:0237.99
FTSHEHFGLLCPKSIUL83Q6SW59HLA class IIDRB1*01:01, DRB1*07:01, DRB1*09:01, DRB5*01:0134.02
YQEFFWDANDIYRIFUL83Q6SW59DRB1*01DRB1*04:01, DRB3*01:01, DQA1*01:01/ DQB1*05:0127.69
RNGFTVLCPKNMIIKUL83Q6SW59HLA-DRDRB1*01:01, DRB1*09:01, DRB1*11:0127.09
RLLQTGIHVRVSQPSUL83Q6SW59DRB1*15, DQA1*01:02/ DQB1*06:02DQA1*01:02/ DQB1*06:0224.17
LRQYDPVAALFFFDIUL83Q6SW59DRB1*07DRB1*07:01, DRB1*09:01,24.01
LPLKMLNIPSINVHHUL83Q6SW59DRB1*03DRB1*01:01, DRB1*04:04, DRB1*09:0121.87
QNLKYQEFFWDANDIUL83Q6SW59HLA class IIDRB5*01:01, DQA1*01:01/ DQB1*05:0118.56
EPDVYYTSAFVFPTKUL83Q6SW59DRB1*07DRB1*15:0118.41
MLDVAFTSHEHFGLLUL83Q6SW59HLA class IIDRB1*07:0118.23
SDVEEDLTMTRNPQPUL83Q6SW59DRB1*03DRB1*03:0117.84
AGILARNLVPMVATVUL83Q6SW59DRB1*11, DRB3*02:02DRB1*01:01, DRB3*02:0211.53
EHPTFTSQYRIQGKLUL83Q6SW59DRB1*11:01DRB1*11:0110.54
TSQYRIQGKLEYRHTUL83Q6SW59DRB1*04, DRB1*13DRB1*11:0110.54
  1. a Experimental restriction found in IEDB; b Experimental plus predicted HLA II restriction/binding (details in Methods); c PPC was computed for 21 different ethnicities around the world